Needham Reiterates Buy on Surmodics, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a 'Buy' rating on Surmodics (NASDAQ:SRDX) and raised the price target from $36 to $50.
August 04, 2023 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics' price target has been raised from $36 to $50 by Needham, with a reiterated 'Buy' rating.
The raised price target and reiterated 'Buy' rating by Needham analyst Mike Matson indicates a positive outlook for Surmodics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100